Open access
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Cheng-Fu Kuo
Zhen Tong
Yi-Chiu Kuo
Miso Park
Jeremy King
Kevin Ly
Bea Parcutela
Lawrence A. Stern
Zhiqiang Wang
J. Hibbard
B. Aguilar
R. Starr
W. Chang
J. Ostberg
Daniela Rossi
Mary C. Clark
D. Alizadeh
Stephan Forman
John C. Williams
Christine E. Brown
Medicine
TL;DR
A versatile and modular platform that enables programmable control of CAR T-cell activity is reported, offering a new strategy to overcome tumor heterogeneity and immune suppression.
Abstract
Treatment of solid tumors with CAR T-cell therapy has proven challenging. The authors report a versatile and modular platform that enables programmable control of CAR T-cell activity, offering a new strategy to overcome tumor heterogeneity and immune suppression.